This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing.
Hereditary cancer in clinical practice · 2025
ASO Author Reflections: Mammographic Microcalcifications in Neoadjuvant Patients: Author Reflections.
Annals of surgical oncology · 2023
Correlation of Mammographic Microcalcifications with Final Surgical Pathology After Neoadjuvant Chemotherapy for Breast Cancer.
Annals of surgical oncology · 2023
Latest funding
- $872,100
Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)
CIHR · 2026 · Co-investigator
- $699,976
Treatment of Ductal Carcinoma In-Situ in Women with a BRCA1 or BRCA2 Pathogenic Variant
CIHR · 2024 · Co-investigator
- $546,976
LOBCAN: a prospective, multi-centre cohort study of treatment and outcomes for invasive LOBular breast carcinoma in CANada.
CIHR · 2024 · Nominated PI
4 publications.
Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing.
Apostol AI, Lim D, Narod SA
ASO Author Reflections: Mammographic Microcalcifications in Neoadjuvant Patients: Author Reflections.
Azam R, Lim D, Curpen B, Mulligan AM, Hong NL
Correlation of Mammographic Microcalcifications with Final Surgical Pathology After Neoadjuvant Chemotherapy for Breast Cancer.
Azam R, Lim D, Curpen B, Mulligan AM, Hong NL
Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy.
Sopik V, Lim D, Sun P, Narod SA
Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)
Principal investigators: Reedijk, Michael
Keywords: Caspase 1; Cytotoxic T Lymphocyte; Il1 Beta; Immune Checkpoint Blockade; Immunotherapy; Notch Signaling; Randomized Control Trial; Triple-Negative Breasat Cancer; Tumor Immune Microenvironment; Tumor-Associated Macrophage
Treatment of Ductal Carcinoma In-Situ in Women with a BRCA1 or BRCA2 Pathogenic Variant
Principal investigators: Kotsopoulos, Joanne; Metcalfe, Kelly A
Keywords: Brca1; Brca2; Ductal Carcinoma In Situ (Dcis); Genetic Testing; Health Outcomes; Invasive Breast Cancer; Observational; Surgery; Survival; Treatment
LOBCAN: a prospective, multi-centre cohort study of treatment and outcomes for invasive LOBular breast carcinoma in CANada.
Principal investigators: Lim, David W
Keywords: Breast Oncology; Health Outcomes; Invasive Breast Cancer; Lobular Breast Cancer; Observational; Prospective Cohort Study; Treatment
An observational study of treatment and outcomes among BRCA1 carriers with breast cancer
Principal investigators: Narod, Steven A
Keywords: Brca1; Breast Cancer; Male Breast Cancer; Survival
Prevention of persistent pain with LidocAine iNfusions in breast cancer surgery (PLAN): a multicentre randomized controlled trial
Principal investigators: Khan, James S; Gilron, Ian
Keywords: Breast Cancer Surgery; Intraoperative Infusion; Lidocaine; Persistent Pain; Prevention; Randomized Controlled Trial
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.